14th Jun 2019 14:11
(Alliance News) - Investment firm Frontier IP Group PLC said Friday its portfolio artificial intelligence drug discovery company Exscientia had entered into a partnership with biotechnology firm GT Apeiron Therapeutics.
Frontier explained that Exscientia - in which it holds a 3.2% stake - will develop a drug-discovery partnership with GT Apeiron.
As part of the deal, Exscientia is entitled to become a shareholder in GT Apeiron as well as receiving milestone and royalty payments based on clinical and commercial success.
Shares in Frontier IP were 0.6% higher at 79.00 pence in London on Friday.
Related Shares:
Frontier Ip